Urogen Pharma (NASDAQ: URGN) and Flex Pharma (NASDAQ:FLKS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Urogen Pharma and Flex Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Urogen Pharma N/A N/A N/A
Flex Pharma -2,655.19% -71.39% -65.49%

Valuation & Earnings

This table compares Urogen Pharma and Flex Pharma’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Urogen Pharma $17.53 million 30.76 -$1.94 million N/A N/A
Flex Pharma $1.01 million 71.70 -$39.49 million ($2.02) -2.00

Urogen Pharma has higher revenue and earnings than Flex Pharma.

Analyst Ratings

This is a breakdown of current ratings for Urogen Pharma and Flex Pharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Urogen Pharma 0 1 4 0 2.80
Flex Pharma 0 1 3 0 2.75

Urogen Pharma presently has a consensus price target of $41.00, suggesting a potential upside of 0.22%. Flex Pharma has a consensus price target of $11.00, suggesting a potential upside of 172.95%. Given Flex Pharma’s higher probable upside, analysts plainly believe Flex Pharma is more favorable than Urogen Pharma.

Insider and Institutional Ownership

37.2% of Urogen Pharma shares are held by institutional investors. Comparatively, 28.8% of Flex Pharma shares are held by institutional investors. 45.4% of Flex Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Urogen Pharma beats Flex Pharma on 8 of the 11 factors compared between the two stocks.

Urogen Pharma Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.

Flex Pharma Company Profile

Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.